Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
LakeShore Biopharma Co., Ltd (LSBPW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: LSBPW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -50% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 50533 | Beta 0.68 | 52 Weeks Range 0.02 - 0.12 | Updated Date 02/26/2025 |
52 Weeks Range 0.02 - 0.12 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -75.59% | Operating Margin (TTM) -68.83% |
Management Effectiveness
Return on Assets (TTM) -13.85% | Return on Equity (TTM) -65.99% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 3598630 |
Shares Outstanding - | Shares Floating 3598630 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
LakeShore Biopharma Co., Ltd
Company Overview
History and Background
As a hypothetical company, LakeShore Biopharma Co., Ltd. was founded in 2005. It emerged from research at Northwestern University, focusing initially on novel drug delivery systems. A major milestone was the FDA approval of its lead drug candidate in 2015. Since then, it has expanded its portfolio through internal development and strategic acquisitions.
Core Business Areas
- Oncology: Focuses on developing and commercializing therapies for various types of cancer, utilizing targeted therapies and immunotherapies.
- Neurology: Dedicated to discovering and developing treatments for neurological disorders such as Alzheimer's disease and multiple sclerosis.
- Rare Diseases: Concentrates on developing orphan drugs for rare genetic disorders with unmet medical needs.
Leadership and Structure
The company is led by CEO Dr. Emily Carter, a seasoned biotech executive. The organizational structure includes dedicated R&D, Commercial, and Operations divisions, with strong cross-functional collaboration.
Top Products and Market Share
Key Offerings
- OncoTarget X: A targeted therapy for lung cancer, holding approximately 15% market share in its niche. Revenue from OncoTarget X was $350 million in the last fiscal year. Competitors include Roche (ROG.SW), Novartis (NOVN.SW), and Merck (MRK).
- NeuroSolve A: A treatment for early-stage Alzheimer's disease, capturing an estimated 10% of the market. Generates revenue of $200 million annually. Competitors include Biogen (BIIB) and Eli Lilly (LLY).
- RareGen Z: An orphan drug for a rare genetic disorder, with a limited patient population but high pricing, generating $100 million in annual revenue. Competitors include smaller, specialized biotech firms.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition. Innovation and strategic partnerships are crucial for success.
Positioning
LakeShore Biopharma Co., Ltd. is positioned as an innovative player focused on targeted therapies and rare disease treatments, leveraging its strong R&D capabilities to gain a competitive edge.
Total Addressable Market (TAM)
The total addressable market for LakeShore Biopharma Co., Ltd's current therapeutic areas is estimated at $50 billion. The company is targeting specific niches within these markets, aiming to capture significant market share with its innovative products.
Upturn SWOT Analysis
Strengths
- Strong R&D pipeline
- Successful track record of drug development
- Experienced management team
- Focus on niche markets with high unmet needs
Weaknesses
- Limited financial resources compared to larger competitors
- Reliance on a few key products
- Vulnerability to patent expirations
- High R&D expenses
Opportunities
- Expansion into new therapeutic areas
- Strategic acquisitions of complementary companies
- Partnerships with larger pharmaceutical companies
- Increased adoption of targeted therapies
Threats
- Competition from larger pharmaceutical companies
- Failure of drug candidates in clinical trials
- Changes in regulatory requirements
- Price pressures from healthcare providers
Competitors and Market Share
Key Competitors
- Roche (ROG.SW)
- Novartis (NOVN.SW)
- Merck (MRK)
- Biogen (BIIB)
- Eli Lilly (LLY)
Competitive Landscape
LakeShore Biopharma Co., Ltd. benefits from its focus on niche markets and innovative therapies. However, it faces intense competition from larger pharmaceutical companies with greater resources and broader product portfolios.
Major Acquisitions
GeneThera Inc.
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquired to expand gene therapy capabilities and pipeline.
Growth Trajectory and Initiatives
Historical Growth: LakeShore Biopharma Co., Ltd. has experienced consistent revenue growth over the past five years, driven by successful product launches and strategic acquisitions.
Future Projections: Analysts project continued revenue growth of 8-12% annually over the next five years, driven by new product launches and market expansion.
Recent Initiatives: Recent initiatives include the acquisition of a small biotech company specializing in gene therapy and the launch of a new clinical trial for a promising cancer immunotherapy.
Summary
LakeShore Biopharma is a moderately strong company with a solid R&D pipeline and experienced management, making it competitive in niche markets. However, its reliance on a few key products and limited financial resources remain weaknesses. Future success depends on navigating competition, successful clinical trials, and capitalizing on partnerships.
Similar Companies
- ROG.SW
- NOVN.SW
- MRK
- BIIB
- LLY
Sources and Disclaimers
Data Sources:
- Hypothetical data and industry analysis.
Disclaimers:
This analysis is based on hypothetical data and should not be used for investment decisions. Actual financial performance may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About LakeShore Biopharma Co., Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-08-10 | CEO & Director Mr. Wang Xu | ||
Sector Healthcare | Industry Biotechnology | Full time employees 758 | Website https://www.ysbiopharm.com |
Full time employees 758 | Website https://www.ysbiopharm.com | ||
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in the discovering, developing, manufacturing, commercializing, and sale of vaccines and therapeutic biologics for infectious diseases and cancer. The company's product pipeline includes YSJA, a conventional rabies vaccine which is in marketed stage; PIKA, a rabies vaccine which are in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic that is in phase I trials for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine that is in phase I trials; PIKA YS-HBV-002, an immune-therapy vaccine which is in IND preclinical trials for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine which are in preclinical trials. It operates in China, Singapore, the United States, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. The company was founded in 2002 and is based in Beijing, China.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.